Sign In
Buy EHVVF
$0.0009
-0.0001 (-10.00%)
At Close: Jun 03, 2026
Ehave Files 6-K Disclosing Research Project Agreement
08:30am, Tuesday, 24'th Aug 2021
MIAMI, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announc
Ehave Releases Additional Information On Partnership With Cutting Edge Data Provider As It Expands Capabilities
08:30am, Tuesday, 13'th Jul 2021
Ehave to provide data integrity and patient privacy while allowing patients to share their medical data with medical providers and research organizations Ehave to provide data integrity and patient pr
Institutional Review Board (IRB) reviews proposed research protocols to protect human subjects involved in research. Institutional Review Board (IRB) reviews proposed research protocols to protect hum
Ehave, Inc. To Be One Of Four Main Sponsors At The Third Annual Psytech Summit on July 19th and 20th, 2021
08:30am, Friday, 02'nd Jul 2021
Sponsorship Opportunity for PsyTech Summit provides robust environment for awareness alongside some of the biggest names in the psychedelic industry Sponsorship Opportunity for PsyTech Summit provides
Health Wizz Co-Founder, Dr. Nitin Desai, To Assist And Advise Ehave On Mental Health Analytical Platforms
08:30am, Tuesday, 29'th Jun 2021
Ehave, Inc. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board. Ehave, Inc. ramps up to begin clinical trials by adding esteemed medical profession
Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer
09:31am, Tuesday, 15'th Jun 2021
New Position Created to Deepen Clinical Expertise and Advance Pipeline Clinical Programs New Position Created to Deepen Clinical Expertise and Advance Pipeline Clinical Programs
Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics
06:30am, Thursday, 20'th May 2021
Brings Ketamine treatments for anxiety, depression and PTSD to the home; Supports Ketamine clinics and mental health professionals. Brings Ketamine treatments for anxiety, depression and PTSD to the h
KetaDASH www.ketadash.com to be the first Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine KetaDASH www.ketadash.com to be the first Intravenous (IV) based
MIAMI, March 12, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today CEO and p
Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021
11:39am, Friday, 26'th Feb 2021
KetaDASH plans to launch beta trial of its ketamine IV therapy using advanced vein technology. KetaDASH plans to launch beta trial of its ketamine IV therapy using advanced vein technology.
Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Technology is Expected to Provide Continuous Monitoring
08:30am, Wednesday, 17'th Feb 2021
Ehave, Inc. to leverage data and AI to correlate biomarkers for the identification of psychedelic drug administration as a treatment for Chronic pain, Depression (major and persistent), PTSD, Bipolar
Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression
08:30am, Monday, 01'st Feb 2021
Ketamine has rapid antidepressant properties in unipolar and bipolar depression. An antidepressant effect has been reported as soon as 40 minutes after ketamine infusions Ketamine has rapid antidepres
Ehave Looks to Expand KetaDASH to Palliative Care
08:30am, Wednesday, 27'th Jan 2021
Palliative patients could benefit from the ketamine home delivery platform, KetaDASH Palliative patients could benefit from the ketamine home delivery platform, KetaDASH
Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare
08:30am, Monday, 25'th Jan 2021
AI has become crucial in developing and simulating predictive models for COVID-19 and psychedelic research in the healthcare industry. AI has become crucial in developing and simulating predictive mod
Ehave Closes Transaction to Acquire CureDash Assets, Adds KetaDASH Home Delivery Service for Ketamine Clinics
08:30am, Friday, 22'nd Jan 2021
Ehave intends to assist Ketamine clinics reach homebound patients by providing access to potentially lifesaving Ketamine infusion therapy for the treatment of psychiatric disorders. Ehave intends to a
